Sponsor or institution
Clinical trials and research at Qilu Pharmaceutical Co., Ltd.
As of November 12, 2026, Find a Trial lists 36 clinical trials run by Qilu Pharmaceutical Co., Ltd. that are recruiting, in China. By phase: Phase 3 (19), Phase 1 (7), Phase 1/2 (6), Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 36Clinical trials
- 1Country
Newest trials
All recruiting trials (36)
-
QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer
This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.
-
First-in-human test of QLS2319 in healthy adults and cancer cachexia
This study tests QLS2319 in healthy adults and people with cancer cachexia to see if it is safe, tolerated, and how it behaves in the body, with a look at early signs of benefit.
-
G-CSF–fusion protein to prevent chemotherapy neutropenia in children with sarcoma
This trial tests Albipagrastim alfa (QLC2519) in children with sarcoma to see if it helps prevent chemotherapy-induced neutropenia.
-
QLS31905 plus CAPOX vs sintilimab plus CAPOX as first-line treatment for gastric/GEJ cancer
This phase 3 trial tests whether QLS31905 with CAPOX works as well as or better than sintilimab with CAPOX for first-line treatment in CLDN18.2-positive, PD-L1 CPS < 5, HER2-negative unresectable or metastatic gastric/GEJ cancer.
-
QLC5508 in Advanced Solid Tumors: Formulations, QTc, PK, and Drug-Drug Interactions
This study tests whether QLC5508 can be safely given to adults with advanced solid tumors and whether two formulations differ in the body, as well as if other drugs change how QLC5508 is processed.
-
QLS5212 in people with advanced solid tumors
This early-phase study tests different doses and schedules of QLS5212 given through IV in adults with unresectable or metastatic solid tumors to see if it is safe and tolerable.
-
Comparing QLC5508 with chemotherapy for previously treated advanced or metastatic esophageal squamous cell carcinoma
This trial tests whether QLC5508 works better than standard chemotherapy for adults with advanced or metastatic esophageal squamous cell carcinoma whose cancer progressed after platinum chemotherapy and an immune checkpoint inhibitor.
-
Meropenem plus pralurbactam versus ceftazidime–avibactam for hospital- and ventilator-associated bacterial pneumonia
This trial will test whether meropenem combined with pralurbactam works as well and is as safe as ceftazidime–avibactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia.
-
QLC5508 combined with other cancer drugs for advanced solid tumors
This will test QLC5508 given with other cancer medicines to see if it is safe and helps adults with advanced solid tumors.
-
QLS1304 with endocrine therapy for advanced ER+/HER2- breast cancer
This trial tests whether adding QLS1304 to standard endocrine therapy is safe and shows early signs of benefit for adults with advanced ER+/HER2- breast cancer who have progressed after prior hormone treatment.
-
QLC5508 and QLH12016 with other anti-tumor therapies in advanced prostate cancer
This study tests QLC5508 and QLH12016, alone or with standard anti-tumor medicines, in men with advanced prostate cancer to see if they are safe and may help control the disease.
-
QLS2309 injections for adults with CD70-positive relapsed or refractory blood cancers.
This trial will try QLS2309 injections to see if they are safe, tolerated, and show early anti-cancer effects in adults with CD70-positive relapsed or refractory blood cancers.
-
QLS32015 versus pomalidomide+dexamethasone or selinexor+dexamethasone for relapsed or refractory multiple myeloma
This will see if QLS32015 alone controls disease and is safe compared with pomalidomide+dexamethasone or selinexor+dexamethasone in adults with relapsed or refractory multiple myeloma who have had at least three prior treatments.
-
Plasma and lung fluid measurements of IV meropenem-pralubactam in healthy Chinese adults
This test measures how much meropenem-pralubactam reaches the blood, epithelial lining fluid, and alveolar macrophages in healthy adults in China.
-
MHB088C treatment for adults with advanced solid tumors
This study will test MHB088C to see if it is safe and shows early signs of benefit in adults with advanced or metastatic solid tumors.
-
Meropenem plus pralurbactam versus best available antibiotics for carbapenem‑resistant Enterobacteriaceae infections
This test compares meropenem combined with pralurbactam to current best available antibiotics for adults hospitalized with serious infections caused by carbapenem‑resistant Enterobacteriaceae.
-
QLS31905 plus chemotherapy versus placebo plus chemotherapy for CLDN18.2-positive advanced pancreatic cancer
This trial will test whether adding QLS31905 to standard chemotherapy helps adults with CLDN18.2-positive advanced pancreatic cancer respond better or live longer than chemotherapy with a placebo.
-
Comparing QL1206 with Prolia® for postmenopausal osteoporosis with high fracture risk
This trial will test whether QL1206 works as well and is as safe as Prolia® for postmenopausal women with osteoporosis who are at high risk of fractures.
-
QLS32015 combination therapy for relapsed or refractory multiple myeloma
This study will test whether the injected drug QLS32015 combined with approved myeloma medicines helps people whose multiple myeloma has come back or not responded to previous treatment.
-
GM1 to prevent nerve damage from albumin-paclitaxel in breast cancer patients.
This trial will test whether GM1 can prevent peripheral nerve damage in adults with breast cancer who are receiving albumin-paclitaxel chemotherapy.
-
MHB088C injection versus physician-chosen chemotherapy for relapsed extensive-stage small cell lung cancer
This study will test whether MHB088C injection can help adults with relapsed extensive-stage small cell lung cancer live longer than chemotherapy their doctor would normally choose.
-
Tafamidis meglumine soft capsules for adults with transthyretin amyloid polyneuropathy
This trial tests whether tafamidis meglumine soft capsules can help adults with transthyretin amyloid polyneuropathy.
-
QLP2117 plus QL2107 for advanced solid tumors
This trial will test the combination of QLP2117 and QL2107 in people with advanced solid tumors who have progressed on or cannot receive standard treatments.
-
QLM3003 ointment for adults with mild to moderate atopic dermatitis
This trial will test whether applying QLM3003 ointment (1.5% or 2%) twice daily for 8 weeks helps adults with mild to moderate atopic dermatitis compared with a placebo.
-
QLS-1304 for adults with advanced malignant solid tumors — Phase 1 dose escalation and expansion
This Phase 1 study tests whether the oral drug QLS-1304 is safe, tolerable, and shows signs of benefit in adults with advanced malignant solid tumors who have exhausted standard treatment options.
-
QL2107 plus chemotherapy versus Keytruda for metastatic non-squamous NSCLC
This test will see if giving QL2107 with pemetrexed and carboplatin works as well as Keytruda (pembrolizumab) with chemotherapy for adults with metastatic non-squamous non-small cell lung cancer who do not have EGFR or ALK mutations.
-
ESG401 as first-line treatment for unresectable recurrent or metastatic triple-negative breast cancer.
This trial will test whether ESG401 works and is safe as a first-line treatment for adults with unresectable recurrent or metastatic triple-negative breast cancer who have not had prior systemic therapy for advanced disease.
-
Evaluating QL1706 for Treating Resectable Colon Cancer
This study is testing a new treatment called QL1706 for people with certain types of colon cancer to see if it can help them during their surgery and recovery.
-
Relugolix treatment for heavy menstrual bleeding from uterine fibroids
This trial will test whether taking relugolix 40 mg once daily can reduce heavy menstrual bleeding in premenopausal women with uterine fibroids compared with placebo.
-
QL0911 to treat chemotherapy-related low platelet counts
This study will try whether QL0911 can raise platelet counts and reduce chemotherapy delays in adults who develop low platelets from cancer treatment.
-
Evaluating QLG1074 for treating active lupus nephritis
This study is testing if a new treatment called QL1074 can help people with active lupus nephritis improve their kidney function when used alongside standard medications.
-
Testing QLC1101 for advanced solid tumors with KRAS G12D mutation
This study is testing a new drug called QLC1101 to see if it can help people with advanced solid tumors that have a specific KRAS G12D mutation, especially those who haven't had success with other treatments.
-
Evaluating ESG401 for advanced breast cancer
This study is testing a new treatment called ESG401 to see if it can help people with advanced breast cancer who haven't had success with other chemotherapy options.
-
Using QLM3004 to slow down myopia in children
This study is testing if a new eye drop called QLM3004 can help slow down worsening eyesight in children aged 6 to 12 who have myopia.
-
Evaluating QLS31903 for advanced solid tumors
This study is testing a new drug called QLS31903 to see if it can help people with advanced solid tumors who haven't had success with other treatments.
-
Combining QL1706 with chemotherapy for lung cancer treatment after surgery
This study is testing if adding a new treatment called QL1706 to standard chemotherapy helps people with stage II-IIIB lung cancer feel better after surgery.
Quick answers
How many clinical trials run by Qilu Pharmaceutical Co., Ltd. are recruiting right now?
36, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 19, Phase 1: 7, Phase 1/2: 6, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.